HoffmanTMWernovskyGAtzAMEfficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107(7):996–1002.
2.
MaltzLAKlugmanDSpaederMCWesselDL.Off-Label Drug Use in a Single Center Pediatric Cardiac Intensive Care Unit. World J. For Pediatric and Congenit. Heart Surg. 2013;4(3):262–266.
3.
DohertyDRPascuetENiAStewartPSplinterWVaillancortR. Off-label drug use in paediatric anaesthesia and intensive care according to official and paediatric reference formularies. Can J Anaesth. 2010;57(12):1078–1088.
4.
HsuBBrazeltonT. Off-label medication use in an academic hospital paediatric critical care unit. WMJ. 2009;108(7):343–348.
5.
YangCPVeltriMAAntonBYasterMBerkowitzID. Food and Drug Administration approval for medications used in the paediatric intensive care unit: a continuing conundrum. Pediatr Crit Care Med. 2011;12(5):e195–e199.
6.
PasqualiSKHallMSloanenADJenkinsKJMarinoBSCohenMSShahSS. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008;1(2):74–83.
7.
LatIMicekSJanzenJCohenHOlsenKHaasC. Off-label medication use in adult critical care patients. J Crit Care. 2011;26(1):89–94.
